Main Uses and Benefits of Glucagon

Glucagon is a hormone naturally produced by the pancreas that plays a critical role in maintaining glucose homeostasis. In a therapeutic context, it is primarily used to manage metabolic conditions where blood sugar levels have dropped to dangerous levels.

Treatment of Severe Hypoglycemia

The primary clinical use of glucagon is the emergency treatment of severe hypoglycemia. This condition occurs when blood glucose levels fall significantly, often as a complication of insulin therapy or other glucose-lowering medications in individuals with diabetes.

Glucagon acts as a fast-acting mobilization agent. When administered, it signals the liver to convert stored glycogen into glucose, which is then released into the bloodstream. This process rapidly elevates blood sugar levels, helping to restore consciousness and prevent neurological complications associated with prolonged glucose deprivation.

Diagnostic Applications

Beyond its role in emergency glucose management, glucagon is utilized in clinical diagnostics, particularly in gastroenterology. Due to its ability to temporarily inhibit the movement (motility) of the digestive tract, it is used during various radiologic and endoscopic examinations.

By relaxing the smooth muscles of the stomach, duodenum, and small bowel, glucagon provides a clearer diagnostic field. This facilitates more accurate imaging and more precise procedures, such as during an endoscopic retrograde cholangiopancreatography (ERCP) or computerized tomography (CT) scans of the gastrointestinal tract.

Physiological Benefits

The primary benefit of glucagon therapy is its ability to provide an immediate metabolic response when oral carbohydrate intake is not possible. Its targeted action on hepatic glucose production makes it a vital tool for:

• Rapid recovery from metabolic crisis: It provides a reliable method to reverse neuroglycopenic symptoms (such as confusion or seizure) when a patient cannot safely swallow.
• Stabilization of glucose levels: By triggering the body's natural glucose reserves, it helps bridge the gap until longer-term nutritional support can be provided.
• Enhanced diagnostic accuracy: In a clinical setting, its secondary effect on muscle relaxation allows for more effective visualization of internal structures.

Who can and cannot use Glucagon

Official regulatory documents define strict eligibility criteria for Glucagon, primarily classifying who may use the medicine for severe hypoglycemia and which groups are formally prohibited.

Glucagon is contraindicated and must not be used in patients diagnosed with pheochromocytoma or insulinoma, as stated in the product labeling. Use is also contraindicated in individuals with known hypersensitivity to the active substance or its excipients.

Age and Comorbidity Eligibility

Efficacy is limited by the patient’s physiological state: the medicine may be ineffective if a patient's hepatic glycogen stores are depleted (e.g., in states of starvation or adrenal insufficiency). This is a critical consideration for use.

Interactions with other medicines and products

The official regulatory profile for Glucagon (Глюкагон) interactions is defined primarily by pharmacodynamic effects on glucose and cardiovascular function. This profile does not document specific interactions involving the CYP450 enzyme system or drug transporters, as Glucagon's clearance is enzymatic and rapid.

Documented Interaction Statements

Interaction-Related Restrictions and Constraints

The regulatory labeling does not list any mandatory administration timing rules or separation requirements for Glucagon co-use. There are no officially listed contraindicated combinations based solely on an interaction mechanism. No specific interactions with food, alcohol, or herbal products are explicitly documented in official regulatory prescribing information. The documented interactions are effect-based, modifying the intended efficacy or the expected cardiovascular response.

Activation of the Glucagon Receptor Signaling Pathway

Glucagon binds to its specific G protein-coupled receptor (GPCR), primarily expressed on hepatocytes (liver cells). This interaction activates the Gs alpha subunit, which in turn stimulates the enzyme adenylyl cyclase. This mechanistic cascade elevates intracellular levels of cyclic adenosine monophosphate (cAMP), resulting in the activation of Protein Kinase A (PKA), the key mediator of downstream cellular effects.

Hepatic and Extrahepatic Pathway Modulation

Activated PKA phosphorylates and regulates enzymes central to metabolic control. In the liver, this promotes glycogenolysis (hydrolysis of glycogen) and gluconeogenesis (glucose synthesis), while simultaneously inhibiting glucose storage. The system-level physiological consequence is the release of stored and newly synthesized glucose into the bloodstream. Extrahepatically, glucagon signaling promotes lipolysis in adipose tissue and the breakdown of amino acids for use as metabolic substrates. Furthermore, it engages the Gs alpha pathway in the gastrointestinal tract, leading to smooth muscle relaxation.

How Glucagon is Used: Official Administration Guidelines

Glucagon is administered according to protocols that vary based on the intended use—emergency treatment or diagnostic aid. All dosing and administration instructions must be followed exactly as stated in the product labeling.

Administration Routes and Dosing

For the emergency treatment of severe hypoglycemia, the standard dose for adults and children weighing 25 kg or more (or 25 kg or ge 6 years) is 1 mg via SC or IM injection, or 3 mg via intranasal powder. Children weighing less than 25 kg (or < 6 years) are typically given 0.5 mg.

Frequency, Preparation, and Follow-up

Glucagon is a single-dose, as-needed medication. For emergency use, if there has been no clinical response after 15 minutes, a single additional dose may be administered using a new kit or device while awaiting emergency medical services.

For use as a diagnostic aid during radiologic examinations to inhibit gastrointestinal movement, Glucagon must be administered only by medical personnel. Doses are lower and administered intravenously or intramuscularly based on the specific organ being examined, such as 0.2 mg to 0.5 mg intravenously for the stomach/small bowel or 0.5 mg to 0.75 mg intravenously for the colon.

Research evidence / Overview of studies for Glucagon

Glucagon for Acute Episodes of Low Blood Sugar

Research has explored how Glucagon was evaluated during conditions involving periods of heightened symptoms related to severely low blood sugar. These studies are typically used in research exploring how symptoms change over time in a rapid, episodic manner, particularly when an individual is unable to eat or drink. The evidence for this use was studied for how it was associated with changes in the body’s systemic or functional imbalance that occurs during these acute events.

The outcomes reflecting daily functioning or activity level that were monitored include changes in consciousness and the body’s sugar levels over a defined time interval. Studies explored Glucagon, particularly in situations where people are unable to take sugar by mouth. Findings indicate that data show patterns related to the blood sugar axis from the body’s stored reserves. This response was observed in some studies to occur within a short, defined time interval. Research highlights changes measured during the study period and reports how the low blood sugar levels evolved in the observed populations. This evidence contributes to understanding these acute symptom patterns.

Limitations and What Remains Uncertain

While Glucagon was evaluated in studies focusing on emergency use, evidence is limited in certain areas. Follow-up durations were limited in many studies, which means that long-term effects are not fully established. Comparative evidence is lacking; evidence quality varies across studies.

The results apply only to the populations studied, and subgroup findings are uncertain for specific populations; data for certain groups remain insufficient. Research provides context but not individual predictions, as findings describe group patterns, not personal outcomes. Evidence highlights what is known — and what is still uncertain regarding its use, and certainty remains low. Research is ongoing to provide further insight into short-term changes and patterns related to outcomes describing episodic or acute changes.

Key Studies & References

1. GLUCAGON- glucagon kit (Full Prescribing Information/DailyMed)

Common questions about Глюкагон (FAQ)

Q: How should Глюкагон be stored?

According to official product information, the glucagon powder kit should be kept at a controlled room temperature, typically between 20 C and 25 C. Once the powder is mixed with the solvent to create the injection, it should be used immediately. The official product information indicates that the reconstituted solution is not intended for storage and should be used right away.

Q: Can I use Глюкагон if it is expired?

Official regulatory documents clearly state that the product must not be used after the expiration date printed on the carton and the container label. For safety and efficacy, official product labeling specifies that the medication should not be used past the expiration date shown on the packaging.

Q: Does Глюкагон affect the heart?

Studies and official information indicate that Glucagon can, in some cases, affect heart rate. Regulatory data lists tachycardia (an increased heart rate) as an adverse reaction that has been reported in clinical experience. Information regarding this or other potential side effects should be discussed with a qualified healthcare provider.

The storage and disposal of glucagon must adhere to official regulatory conditions to ensure stability and safe handling. The unopened product should be stored in its original package, protected from light.

Storage Conditions

Disposal Instructions

Any unused portion of the reconstituted solution must be discarded. Single-dose devices must not be reused. Used needles and syringes (sharps) must be disposed of immediately in a puncture-resistant container according to local guidelines for safe pharmaceutical waste and sharps disposal. Do not dispose of loose sharps in household trash.